BioSpace News Archive

This webinar, tailored for scientists in academia, biotech, and pharma, will explore how intelligent mRNA designs can reduce experimental workloads and improve mRNA performance and efficacy.

This webinar examines how immune memory in allergic individuals may offer new therapeutic possibilities. Pr. Pierre Bruhns presents his team’s research on characterizing antibody repertoires specific to the neuromuscular blocker rocuronium. Discover how these antibodies contribute to anaphylactic reactions and how they could support the development of diagnostic tools and therapeutic agents to reverse neuromuscular blockade.

Stellaromics

After spinning out of BridgeBio in May 2024, BBOT had an eye on another round of fundraising in 2025. A SPAC quickly emerged as the best option.

Some of the biggest SPACs from the industry’s pandemic-fueled heyday are no longer on the market.

Blank check deals dwindled after a crazy 2021. Now, biotechs are starting to turn to special purpose acquisition companies again as an easy route to the public markets.

It can cure deadly diseases, save long-term healthcare costs and transform lives. But the U.S. insurance system still isn’t ready to pay for it.

Health Secretary Robert F. Kennedy Jr. will appear before the Senate Finance Committee Thursday, ahead of a vaccine advisory committee meeting later in September. Meanwhile, deal-making appetite appears healthy, and the weight loss space continues generating clinical data and other news.

Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.